Biogen’s stock jumped on Wednesday A South Korean newspaper reported Samsung Group was in talks to acquire the drugmaker.
A Samsung spokesperson told baron’s In an emailed statement that the report was baseless.
The Korea Economic Daily, citing unnamed investment banking sources, reported that Samsung is in talks to acquire Biogen (ticker: BIIB). According to the report, the deal could value Biogen at $42 billion. This represents a nearly 20% premium to Biogen’s current market cap of approximately $35 billion.
Biogen said it does not comment on market rumors and/or speculation.
Biogen stock closed up 9.5% at $258.31 on Wednesday, posting a 5.5% year-over-year gain.
“The reported takeout valuation of $42B represents a relatively small acquisition premium and is well below our equity valuation of $52B ($53B EV – $7B debt + $6B cash),” said Jay Olsen, analyst at Oppenheimer. baron’s, “A $42 billion deal appears to be taking unfortunate advantage of the current crisis situation. We would love to see a takeout for Biogen well above our $350 per share target price.”
Earlier this year, the company’s EduHelm drug, an Alzheimer’s disease therapy, was approved by the US Food and Drug Administration, despite some concerns from doctors and researchers. Drug sales in the third quarter were only $300,000, well below estimates of $12.1 million. The company said in December that it would cut the cost of therapy in half to $27,200 a year for a patient of average weight.
Write to Connor Smith at [email protected]